Company Directory - Research & Development
The clinical development of drugs and devices is crucial for human welfare. Our mission is to improve success rates in this endeavor.
We do this by improving the design and implementation of clinical trials through the innovative application of stat
DNA Script was created to revolutionize DNA write with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAXTM, the world’s first benchtop DNA printer powered by enzymatic technology.
We discover and develop medicines to defeat neurodegeneration. We are applying deep scientific and drug development expertise to discover effective molecular therapeutics and have engineered a proprietary technology to deliver biologic therapeutics to the brain.
At DiCE Molecules, we design and develop innovative therapies in immunology for patients with chronic diseases. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms.
ERBER Group is a group of healthy and profitable businesses which are aligned for organic growth on a global scale and show a strong ability to innovate. We are a leading group of companies in the field of food and feed safety, focusing on natural feed additives as well as feed and food analysis, and headquarters in Austria.
Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing, distribution and marketing, with a strong focus on prescription medicines.
Enara Bio™ (formerly known as Ervaxx) is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population.
We are fully equipped and well-positioned to realize the potential of Encoded’s novel approach to gene therapy for people living with pediatric central nervous system (CNS) diseases and their families.
We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high medical need.
Epithelix Sàrl provides alternative in vitro solutions to animal experimentation for evaluating the effects of drugs in development and assess the toxicity of chemical compounds on the human respiratory tract. Epithelix is a biotech company founded in March 2006 and located in Geneva, Switzerland.
We research, develop and commercialize high quality, affordable, ready-to-formulate ingredients that are based on nature and are available at all times, in any quantity. We believe in applying technology platforms, such as fermentation, to help resolve sourcing bottlenecks in nature.
F2G is a world-leading UK- and Austria-based Biotech company (F2G Ltd and F2G Biotech GmbH) focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides.
Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases.
GBT is working to discover, develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease. Our goal is to transform the treatment of sickle cell disease (SCD), an overlooked rare condition, and help address the urgent needs of the community.
Genialis is a computational precision medicines company unravelling complex biology to find new ways to address disease. ResponderID™, Genialis’ clinical biomarker discovery platform, defines, models, and validates actionable biomarkers and optimally positions novel drugs to accelerate translational research and clinical development.
Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
We deliver the understanding of the genomic drivers of every disease for Pharma. Our curated Genomic Landscapes provide immediate insight into the genomic evidence for every phenotype, disease, gene, and variant.
